Selected article for: "clinical trial and infection control"
Author: Shitao Rao; Alexandria Lau; Hon-Cheong So
Title: Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization analysis
  • Document date: 2020_3_8
    • ID: myh73pe6_43
    Snippet: In a similar vein, if resources are limited, the more susceptible subjects may receive higher priority for diagnostic testing for the infection. As far as treatment is concerned, if certain conditions such as diabetes indeed increases susceptibility via ACE2, then drugs targeting at this gene/protein may be particularly useful for this patient subgroup. For example, human recombinant ACE2 has been proposed as a treatment and is under clinical tri.....
    Document: In a similar vein, if resources are limited, the more susceptible subjects may receive higher priority for diagnostic testing for the infection. As far as treatment is concerned, if certain conditions such as diabetes indeed increases susceptibility via ACE2, then drugs targeting at this gene/protein may be particularly useful for this patient subgroup. For example, human recombinant ACE2 has been proposed as a treatment and is under clinical trial for COVID-19 35 . It will be interesting to see if the drug may be more beneficial for DM patients. More generally speaking, if DM is causally linked to elevated ACE2 and potentially increased susceptibility to infection, then anti-diabetic drugs or improved glycemic control may reverse the process.

    Search related documents:
    Co phrase search for related documents
    • anti diabetic drug and improve glycemic control: 1
    • certain condition and clinical trial: 1
    • clinical trial and diagnostic testing: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical trial and gene protein: 1, 2, 3, 4
    • clinical trial and glycemic control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • clinical trial and high priority: 1, 2, 3, 4, 5
    • clinical trial and improve glycemic control: 1, 2, 3
    • clinical trial and infection susceptibility: 1, 2, 3, 4, 5, 6
    • clinical trial and patient subgroup: 1
    • diagnostic testing and gene protein: 1, 2, 3, 4, 5
    • diagnostic testing and gene protein target: 1
    • diagnostic testing and glycemic control: 1
    • diagnostic testing and high priority: 1, 2, 3, 4
    • diagnostic testing and infection diagnostic testing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • diagnostic testing and infection susceptibility: 1
    • drug gene protein target and gene protein: 1, 2
    • drug gene protein target and gene protein target: 1, 2
    • gene protein and infection susceptibility: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • gene protein and infection susceptibility increase: 1